CN110809580A - 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 - Google Patents

用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 Download PDF

Info

Publication number
CN110809580A
CN110809580A CN201880020694.1A CN201880020694A CN110809580A CN 110809580 A CN110809580 A CN 110809580A CN 201880020694 A CN201880020694 A CN 201880020694A CN 110809580 A CN110809580 A CN 110809580A
Authority
CN
China
Prior art keywords
seq
hla
antibody
peptide
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880020694.1A
Other languages
English (en)
Chinese (zh)
Inventor
乔恩·韦丹兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Ambergris Biologics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambergris Biologics filed Critical Ambergris Biologics
Publication of CN110809580A publication Critical patent/CN110809580A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201880020694.1A 2017-01-24 2018-01-24 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 Pending CN110809580A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762449954P 2017-01-24 2017-01-24
US62/449,954 2017-01-24
US201762460585P 2017-02-17 2017-02-17
US62/460,585 2017-02-17
PCT/US2018/015086 WO2018140525A1 (en) 2017-01-24 2018-01-24 Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer

Publications (1)

Publication Number Publication Date
CN110809580A true CN110809580A (zh) 2020-02-18

Family

ID=62979691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880020694.1A Pending CN110809580A (zh) 2017-01-24 2018-01-24 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物

Country Status (5)

Country Link
US (1) US20190071502A1 (cg-RX-API-DMAC7.html)
EP (1) EP3573997A4 (cg-RX-API-DMAC7.html)
JP (2) JP7303750B2 (cg-RX-API-DMAC7.html)
CN (1) CN110809580A (cg-RX-API-DMAC7.html)
WO (1) WO2018140525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP4461371A3 (en) 2014-12-23 2025-02-26 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
CA3107001A1 (en) * 2018-07-23 2020-01-30 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
KR20210089193A (ko) * 2018-11-01 2021-07-15 버클리 라잇츠, 인크. 미세유체 디바이스에서 생물학적 세포를 분석하기 위한 방법
AU2020312163A1 (en) * 2019-07-05 2022-02-17 Intellexon Gmbh HLA-H in medicine and diagnostics
CN110491450B (zh) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 肿瘤新生抗原预测平台及其应用
JP2022553073A (ja) * 2019-10-25 2022-12-21 インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療・診断標的としてのｈｌａ－ｈ， ｈｌａ－ｊおよびｈｌａ－ｌ
CA3183756A1 (en) * 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
KR20230015996A (ko) * 2020-06-30 2023-01-31 하버 바이오메드 (상하이) 컴퍼니 리미티드 H2l2 및 hcab 구조를 갖는 결합 단백질
WO2022060893A1 (en) * 2020-09-15 2022-03-24 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
EP4388012A4 (en) * 2021-08-20 2025-09-17 Univ Duke ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES
JPWO2023112965A1 (cg-RX-API-DMAC7.html) * 2021-12-15 2023-06-22
KR20250099771A (ko) * 2022-10-05 2025-07-02 티스캔 테라퓨틱스, 인크. Magea1 면역원성 펩타이드, magea1 면역원성 펩타이드를 인식하는 결합 단백질 및 이의 용도
WO2024084091A1 (en) * 2022-10-21 2024-04-25 Medizinische Universität Wien Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases
TW202513802A (zh) * 2023-09-22 2025-04-01 美商再生元醫藥公司 獲得與多肽－ｍｈｃ界面結合的抗體分子之方法
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252076A (zh) * 1997-04-14 2000-05-03 麦可麦脱生物药学研究有限公司 抗人抗原受体的新的生产方法及其用途
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
WO2013075105A2 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Tcl1 peptides for immunotherapy
CN105980557A (zh) * 2013-12-04 2016-09-28 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
US20160279218A1 (en) * 2015-03-27 2016-09-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019439B1 (en) * 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
JP2010519256A (ja) * 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
WO2008120202A2 (en) * 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
GB201003198D0 (en) * 2010-02-25 2010-04-14 Arab Biotechnology Company Compositions and methods for the treatment of cancer
BR112013002532A2 (pt) * 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
US10656156B2 (en) * 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
RU2018102526A (ru) * 2015-06-24 2019-07-25 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252076A (zh) * 1997-04-14 2000-05-03 麦可麦脱生物药学研究有限公司 抗人抗原受体的新的生产方法及其用途
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
WO2013075105A2 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Tcl1 peptides for immunotherapy
CN105980557A (zh) * 2013-12-04 2016-09-28 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
US20160279218A1 (en) * 2015-03-27 2016-09-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors

Also Published As

Publication number Publication date
EP3573997A1 (en) 2019-12-04
JP7303750B2 (ja) 2023-07-05
JP2020506962A (ja) 2020-03-05
US20190071502A1 (en) 2019-03-07
JP2023134503A (ja) 2023-09-27
WO2018140525A1 (en) 2018-08-02
EP3573997A4 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
JP7303750B2 (ja) 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
US20240166751A1 (en) Hla-restricted epitopes encoded by somatically mutated genes
US20200291128A1 (en) Antibodies and methods of use thereof
JP5982698B2 (ja) Ｄｌｌ４に特異的に結合する新規モノクローナル抗体及びその用途
US9273136B2 (en) Fully human anti-human NKG2D monoclonal antibodies
JP7013243B2 (ja) 微細特異性を有する親和性結合体
US20210147572A1 (en) Antibodies and methods of use thereof
Cohen et al. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies
KR102225422B1 (ko) 치료 펩티드
RU2488593C2 (ru) Человеческое опухолеспецифическое моноклональное антитело
CN112533955A (zh) 抗b7-h3抗体
IL280890B1 (en) Antigen-binding proteins targeting shared antigens
CN102099376A (zh) 针对her2的细胞外结构域2和3的抗体
US20200291127A1 (en) Antibodies and methods of use thereof
US20200291116A1 (en) Antibodies and methods of use thereof
NL2024375B1 (en) Methods and means for attracting immune effector cells to tumor cells.
EP3655026A2 (en) Antigen binding regions against fibronectin type iii domains and methods of using the same
Verma et al. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties
US12072337B2 (en) Circulating tumor cell enrichment using neoepitopes
US12006373B1 (en) Identification and evaluation of novel peptide ligands specific to human CD3 epsilon
WO2024133584A2 (en) Antigen binding proteins
HK40091002A (zh) 由体细胞突变基因编码的hla限制性表位

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220420

Address after: Connecticut, USA

Applicant after: Boehringer Ingelheim Pharmaceuticals

Address before: Texas, USA

Applicant before: Ambergris biologics

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200218